Literature DB >> 7148363

Malignant hyperthermia in a myopathic child. Prolonged postoperative course requiring dantrolene.

R Fletcher, G Blennow, A K Olsson, E Ranklev, K Törnebrandt.   

Abstract

An 18-month-old boy with congenital muscular dystrophy began to develop clear signs of the malignant hyperthermia syndrome after 85 min of halothane/nitrous oxide anaesthesia. Dantrolene, 2 mg/kg i.v., was immediately effective, but temperature, heart rate and carbon dioxide production were all increased for 2 days postoperatively in spite of repeated dantrolene administration.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7148363     DOI: 10.1111/j.1399-6576.1982.tb01795.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  3 in total

Review 1.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

2.  Postoperative malignant hyperthermia and dantrolene therapy.

Authors:  U Schulte-Sasse; W Hess; H J Eberlein
Journal:  Can Anaesth Soc J       Date:  1983-11

3.  C1840-T mutation in the human skeletal muscle ryanodine receptor gene: frequency in northern German families susceptible to malignant hyperthermia and the relationship to in vitro contracture response.

Authors:  M Steinfath; S Singh; J Scholz; K Becker; C Lenzen; F Wappler; A Köchling; N Roewer; J Schulte am Esch
Journal:  J Mol Med (Berl)       Date:  1995-01       Impact factor: 4.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.